Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
With crowdfunding websites like Kickstarter and Indiegogo, companies can obtain the funding for ideas they want to come to life (even potato salad parties), with the promise of something in return to the donors. And while crowdfunding presents challenges for regulated medical devices, it’s proven to be a boon for startups touting potentially innovative health and wellness devices to consumers. Read more
Conventus Orthopaedics said today it closed a $20 million round of financing to support its Conventus Cage implant device designed for 3D fixation and fracture repair.
The Conventus Cage is designed to allow for a “less invasive” reliable 3D fixation for treating proximal humerus, distal radius and proximal radius fractures, the company said. Read more
Abbott said today that the TactiCath sensor-enabled ablation catheter it bought along with St. Jude Medical this year won CE Mark approval in the European Union.
The Chicago-area healthcare giant said the new TactiCath device can be integrated with another St. Jude product, the EnSite Precision heart mapping system it launched earlier this year. Read more
Boston Scientific said today that it won pre-market approval from the FDA for its Resonate line of defibrillators featuring multi-lead pacing.
The Marlborough, Mass.-based medical device maker said the Resonate implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators also feature its SmartCRT technology and EnduraLife battery technology that it claims delivers twice the usable battery capacity of competing devices. Read more
The U.S. Senate’s Health, Education, Labor & Pensions Committee this week floated an updated “manager’s amendment” to the House bill reauthorizing the user fee deal between the FDA and the medical device and drug industries.
The HELP panel’s amendments, issued ahead of a committee vote slated for tomorrow, include all of the elements hammered out in 2-year negotiations to date. It also includes a trio of new sections covering device facility inspections and regulatory improvements, pediatric devices and drugs and clinical trial requirements, according to Regulatory Affairs. Read more